Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc.

SGMOQ - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$49.71M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Sangamo Therapeutics, Inc.Sangamo Therapeutics, Inc.0--468188%--

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$49.71 Million
Enterprise Value$49.71 Million
Earnings per Share$-
Beta1.4
Outstanding Shares-

Return

Return on Equity-468187.69%ROE
Return on Assets-85789.41%
Return on Invested Capital-87410.88%

Valuation & Multiples

P/E Ratio-P/E Ratio
PEG-PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue1.44
Enterprise Value to EBIT-0.4
Enterprise Value to Net Income-1
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 17, 2026
EPS
-$0.08
Est. $0.01
Revenue
$1.44 M
Est. $33.73 M

Next Earnings Call

Expected Date
February 24, 2027
EPS Estimate
-$0.07
Consensus analyst estimate
Revenue Estimate
$1.50 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Sangamo Therapeutics Inc

142 employees
CEO: Alexander Macrae

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The firm focuses on three therapeutic areas: inherited metabolic diseases, central nervous syste...